<DOC>
	<DOCNO>NCT03054298</DOCNO>
	<brief_summary>Phase I study establish safety feasibility intravenous intrapleural administer lentiviral transduce huCART-meso cell without lymphodepletion . Intravenous administration huCART-meso cell plan without cyclophosphamide lymphodepleting chemotherapy .</brief_summary>
	<brief_title>CAR T Cells Mesothelin Expressing Cancers</brief_title>
	<detailed_description>This Phase I study evaluate safety feasibility lentiviral transduce huCART-meso cell 5 cohort without cyclophosphamide 3+3 dose escalation design . Cohort 1 subject ( N=3-6 ) receive single dose 1-3x107 /m2 lentiviral transduce huCART-meso cell day 0 without condition chemotherapeutic regimen . Cohort 2 subject ( N=3-6 ) receive single dose 1-3x107 /m2 lentiviral transduce huCART-meso cell day 0 , follow flat dose 1 grams/m2 cyclophosphamide administer 2-4 day prior huCART-meso cell ( day - 4 day -2 ) . Cohort 3 subject ( N=3-6 ) receive single dose 1-3x108 /m2 lentiviral transduce huCART-meso cell day 0 without condition chemotherapeutic regimen . Cohort 4 subject ( N=3-6 ) receive single dose 1-3x108 /m2 lentiviral transduce huCART-meso cell day 0 , follow flat dose 1 gram/m2 cyclophosphamide administer 2-4 day prior huCART-meso cell ( day -4 day -2 ) . Cohort 5 subject ( N=up 6 ) receive single dose 1-3x107 /m2 lentiviral transduce huCART-meso cell day 0 intrapleural infusion ( IP ) indwell pleural catheter without condition chemotherapeutic regimen . Subjects cohort enrol safety demonstrate dose level completion Cohorts 1 2 . Subjects Cohort 5 may enrol parallel Cohorts 3 4 . The Maximum Tolerated Dose ( MTD ) define dose 0-1 DLT occur 6 evaluable subject test within dose range study . In order gather additional data MTD dose level , respective cohort ( without lymphodepletion ) may expand treat 6 evaluable subject . Adverse event collect evaluate protocol specify adverse event reporting period .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histologically confirm cancer ( one follow ) : Cohorts 14 patient : Metastatic recurrent lung adenocarcinoma . Persistent recurrent serous epithelial ovarian cancer primary peritoneal carcinoma fallopian tube carcinoma Malignant pleural peritoneal mesothelioma ( histologically confirm epithelial ) Cohort 5 patient : Metastatic recurrent lung adenocarcinoma document pleural effusion Persistent recurrent serous epithelial ovarian cancer primary peritoneal carcinoma fallopian tube carcinoma document pleural effusion Malignant pleural peritoneal mesothelioma ( histologically confirm epithelial ) document pleural effusion Confirmation tumor mesothelin expression ( ≥50 % tumor cell ) Failure least one prior standard care chemotherapy advance stage disease . Prior therapy PD1 PDL1 permissible &gt; 4 week enrollment . Subjects must measureable disease define RECIST 1.1 criterion modify RECIST criterion . Patients asymptomatic CNS metastasis treat steroid allow . They must meet following time enrollment : No concurrent treatment CNS disease No progression CNS metastasis MRI screening scan No evidence leptomeningeal disease cord compression Patients &gt; 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Satisfactory organ bone marrow function define follow : Absolute neutrophil count &gt; 1,000/μl Platelets &gt; 75,000/μl Hemoglobin &gt; 9 g/dL Bilirubin &lt; 2.0x institutional normal upper limit unless secondary bile duct obstruction tumor Creatinine &lt; 1.5x institutional normal upper limit Albumin ≥2 Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5x institutional normal upper limit Cardiac ejection fraction &gt; 40 % measure rest echocardiogram , clinically significant pericardial effusion . Blood coagulation parameter : PT international normalize ratio ( INR ) ≤ 1.5 PTT &lt; 1.2 time upper limit normal unless patient therapeutically anticoagulated history cancerrelated thrombosis stable coagulation parameter . Provides write informed consent . Subjects reproductive potential must agree use acceptable birth control method Sarcomatoid mesothelioma histology know literature express mesothelin ; biphasic mesothelioma also exclude . Known leptomeningeal carcinomatosis spinal cord compression . Screening required unless suspicious symptom . Patients symptomatic CNS metastasis exclude . Participation therapeutic investigational study within 4 week prior enrollment , anticipate treatment another investigational product study . This refer noncommercially approve investigational drug different use protocol . Active invasive cancer one three cancer study . Patients active noninvasive cancer ( nonmelanoma skin cancer , superficial cervical bladder prostate cancer PSA level &lt; 1.0 ) exclude . HIV infection Active hepatitis B hepatitis C infection Active autoimmune disease ( include limit : systemic lupus erythematosus , Sjogren 's syndrome , rheumatoid arthritis , psoriasis , multiple sclerosis , inflammatory bowel disease , etc . ) require immunosuppressive therapy within 4 week prior enrollment visit , exception thyroid replacement . Patients ongoing active infection . Planned concurrent treatment systemic high dose corticosteroid . Patients may stable low dose steroid ( &lt; 10mg equivalent prednisone ) chronic respiratory condition adrenal insufficiency . Corticosteroids treatment antiemetic prophylaxis day cyclophosphamide administration allow per institutional guidance . Patients require supplemental oxygen therapy . Prior therapy lentiviral gene modify cell . History allergy hypersensitivity study product excipients ( human serum albumin , DMSO , Dextran 40 ) Any clinically significant pericardial effusion , Class IIIV cardiovascular disability accord New York Heard Association Classification ( see Appendix 2 ) cardiovascular condition would preclude assessment mesothelin induce pericarditis may worsen result toxicity expect study . This determination make cardiologist cardiac issue suspect . Any clinically significant pleural peritoneal effusion drain standard approach . An indwelling drainage device place prior enrollment acceptable . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>